1[1]Bristow AF. WHO international standards for highly purified human, porcine and bovine insulins. Jbid stand, 1988,16:165 被引量：1
2[2]Buchana J, Lee H B,Lauper R D. Recombinant DNA technology.Journal of pharmacy practice. 1991,4: 87～ 93 被引量：1
3[3]Volund A. IN vitro and in vivo potency of insulin analogues designed for clincal use. Diabetic Med,1991,8:839 被引量：1
4[4]Robbins D C. Task Force Report :Report of the American diabetes association's task force on standardization of the insulin assay, diabetes, 1996,45: 242 被引量：1
7[7]NOVO Nordisk: Specification and quality control methods prota HM 1995 被引量：1
8[8]Farid N A. Liquid chromatographic control of the identity,purity and "potency" of biomolecules used as drugs. J pharm biomed Anal, 1989,7. 185 被引量：1
2Roth J,Qureshi S,Whitford I,et al.Insulin’s discovery:new insights on its ninetieth birthday[J].Diabetes Metab Res Rev,2012,28(4):293. 被引量：1
3Akram M,Naqvi SB,Khan A.Design and development of insulin emulgel formulation for transdermal drug delivery and its evaluation[J].Pak J Pharm Sci,2013,26(2):323. 被引量：1
5Robbins DC,Andersen L,Bowsher R,et al.Report of the American diabetes association’s task force on standardization of the insulin assay[J].Diabetes,1996,45(2):242. 被引量：1
